Retour
Explorez tous les épisodes du podcast The Long Run with Luke Timmerman
Plongez dans la liste complète des épisodes de The Long Run with Luke Timmerman. Chaque épisode est catalogué accompagné de descriptions détaillées, ce qui facilite la recherche et l'exploration de sujets spécifiques. Suivez tous les épisodes de votre podcast préféré et ne manquez aucun contenu pertinent.
| Titre | Date | Durée | |
|---|---|---|---|
| Ep206: Lyn Baranowski on Inhalable Medicines for Severe Lung Diseases | 28 juil. 2026 | 01:07:17 | |
Lyn Baranowski, CEO of Boston-based Avalyn Pharma, on developing inhalable medicines for severe lung diseases. | |||
| Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With | 14 juil. 2026 | 01:08:18 | |
Heather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to better cross the blood-brain barrier, be dosed once daily, and make it easier for patients to take long term. | |||
| Ep204: Troy Wilson on Precision Cancer Drugs and Combos | 30 juin 2026 | 01:07:27 | |
Troy Wilson, CEO of San Diego-based Kura Oncology, on his career in biotech and developing targeted cancer drugs. | |||
| Ep203: Sri Kosuri on Small Molecule Correctors of Disease | 16 juin 2026 | 01:11:43 | |
Sri Kosuri, co-founder and CEO of Emeryville, Calif.-based Octant Bio, on small molecules designed to correct protein misfolding and mistrafficking at the root of many diseases. | |||
| Ep202: Becky Pferdehirt on Reimagining Science for the AI Era | 02 juin 2026 | 01:08:12 | |
Becky Pferdehirt, CEO of Emeryville, CA-based Radial, the life sciences unit of Astera Institute, on reimagining biology to take advantage of advances in AI. | |||
| Ep201: Jeremy Levin on Biotech in the Balance | 19 mai 2026 | 01:08:40 | |
Jeremy Levin, executive chair of Ovid Therapeutics, discusses his new book "Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust." | |||
| Ep200: Richard Pops Reflects on a 35-Year Career in Biotech | 05 mai 2026 | 01:13:31 | |
Alkermes CEO Richard Pops reflects on his 35-year career leading the company and its new opportunity in orexin biology for sleep disorders and more neurological conditions. | |||
| Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era | 21 avr. 2026 | 01:10:08 | |
Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI. | |||
| Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery | 07 avr. 2026 | 01:16:43 | |
Abbas Kazimi, CEO of Boston-based Nimbus Therapeutics, on computation and culture for drug discovery. | |||
| Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature | 31 mars 2026 | 01:16:57 | |
Viswa Colluru, founder and CEO of Boulder, Colo.-based Enveda, on drug discovery with a chemistry platform inspired by natural products. | |||
| Ep196: Otello Stampacchia on Europe's Biotech Crisis | 17 mars 2026 | 01:03:17 | |
Otello Stampacchia, founder and managing director of Omega Funds, on attempting to reform Europe's biotech investment climate. | |||
| Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases | 03 mars 2026 | 01:05:45 | |
Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease. | |||
| Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery | 17 févr. 2026 | 01:08:54 | |
Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery by Timmerman Report | |||
| Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines | 22 janv. 2026 | 01:05:10 | |
Ron Renaud, CEO of Waltham, Mass.-based Kailera Therapeutics, on developing GLP-1 based medicines to help people lose weight and live healthier lives. | |||
| Ep192: Kate Haviland on Following the Science to Precision Immunology | 08 janv. 2026 | 01:26:06 | |
Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion. | |||
| Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease | 15 déc. 2025 | 01:07:34 | |
Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD). | |||
| Ep190: Neil Kumar on Building a Rare Disease Drug Company | 20 nov. 2025 | 01:13:12 | |
Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer. | |||
| Ep189: Marc Tessier-Lavigne on Reinventing Drug Discovery with AI | 12 nov. 2025 | 01:12:33 | |
Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics, on reinventing drug discovery with AI. | |||
| Ep188: Art Krieg on Innate Immune System Activators for Cancer | 28 oct. 2025 | 01:09:05 | |
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer. | |||
| Ep187: Eric Fischer on Creating a New Class of Medicines | 14 oct. 2025 | 01:05:48 | |
Eric Fischer, a professor at Dana-Farber Cancer Institute, on creating a new class medicines -- targeted protein degraders. | |||
| Ep186: Bruce Levine & Mags McCarthy on a Song About Science and Hope | 29 sept. 2025 | 01:02:33 | |
Bruce Levine, a CAR-T cell therapy researcher at the University of Pennsylvania, and Mags McCarthy, a country music star, discuss their new song about science and hope for cancer patients. | |||
| Ep185: Dr. Lachelle Weeks on Predicting Leukemia Risk At Scale | 17 sept. 2025 | 01:05:47 | |
Dr. Lachelle Weeks is a physician-scientist at Dana-Farber Cancer Institute working on a project to predict leukemia risk based on widely available blood samples. | |||
| Ep184: Jen Adair on Affordable, Accessible Gene & Cell Therapies | 28 août 2025 | 01:50:23 | |
Jen Adair, professor and associate director of the Horae Gene Therapy Center at the University of Massachusetts Chan Medical School, on creating more affordable and accessible cell and gene therapies. | |||
| Ep183: Sabah Oney on CAR-T Cells Against Solid Tumors | 06 août 2025 | 00:56:23 | |
Sabah Oney, CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics, on engineering CAR-T cells that can kill solid tumors. | |||
| Ep182: Andy Rachleff & Yung Lie on Creative Ways to Back Science | 23 juil. 2025 | 01:01:18 | |
Andy Rachleff and Yung Lie, board chair and CEO of Damon Runyon Cancer Research Foundation, on creative ways to support science amid budget cuts. | |||
| Ep181: Claire Mazumdar on a Two-Pronged Attack Against Cancer | 01 juil. 2025 | 00:57:18 | |
Claire Mazumdar, CEO of Boston-based Bicara Therapeutics, on developing a bifunctional antibody for head and neck cancer. | |||
| Ep180: John Rinn on Discovering Drugs Based on Long Non-Coding RNA | 11 juin 2025 | 01:10:45 | |
John Rinn, professor at the University of Colorado and co-founder of Lincswitch Therapeutics, on exploring long non-coding RNA. | |||
| Ep179: Ethan Weiss & Josh Lehrer on a New Idea for Cardiovascular Disease & Diabetes | 28 mai 2025 | 01:03:25 | |
Marea Therapeutics CEO Josh Lehrer and CSO Ethan Weiss on a new angle of attack against cardiovascular disease and diabetes. | |||
| Ep178: Peyton Greenside on ML-Guided Biologics Discovery | 13 mai 2025 | 01:02:56 | |
Peyton Greenside, co-founder and CEO of BigHat Biosciences, on machine-learning guided biologic drug discovery. | |||
| Ep177: Kevin Parker on Finding Cancer Drug Targets | 14 avr. 2025 | 00:58:13 | |
Kevin Parker, CEO of Cartography Biosciences, on finding new cancer drug targets. | |||
| Ep176: David Roblin on Building a TechBio Company | 31 mars 2025 | 01:19:28 | |
David Roblin, CEO of London-based Relation Therapeutics, on building a techbio discovery company. | |||
| Ep175: Andy Scharenberg on in vivo CAR-T cell therapies | 16 mars 2025 | 01:10:46 | |
Andy Scharenberg, CEO of Seattle-based Umoja Biopharma, on developing in vivo CAR-T cell therapies. | |||
| Ep174: Najat Khan on the TechBio Movement | 03 mars 2025 | 01:07:16 | |
Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery. | |||
| Ep173: Robert Blum on Building a Fully Integrated Biopharma For Muscle Disorders | 11 févr. 2025 | 00:57:56 | |
Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders. | |||
| Ep172: Mostafa Ronaghi on Studying Live Cells at Scale | 27 janv. 2025 | 01:20:53 | |
Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale. | |||
| Ep171: Ram Aiyar on RNA Editing Medicines | 13 janv. 2025 | 01:01:48 | |
Ram Aiyar, CEO of Cambridge, Mass.-based Korro Bio, on RNA editing medicines. | |||
| Ep170: David Schenkein on Investing in the Future of Biotech | 02 janv. 2025 | 00:59:52 | |
David Schenkein, general partner at GV, on investing in the future of biotech. | |||
| Ep169: Kevin Fitzgerald on the Past & Future of RNAi Medicines | 11 déc. 2024 | 01:02:28 | |
Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines. | |||
| Ep168: Jonathan Bricker on How to Quit Smoking & Prevent Cancer | 25 nov. 2024 | 01:00:23 | |
Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools. | |||
| Ep167: Leslie Williams on transfer RNA therapies | 06 nov. 2024 | 01:11:28 | |
Leslie Williams, CEO of Boston-based hC Bioscience, on developing transfer RNA therapies. | |||
| Ep166: Chris Garcia on Engineering Protein Drugs for Cancer, Autoimmunity | 15 oct. 2024 | 01:03:35 | |
Chris Garcia, professor at Stanford University and co-founder of several biotech startups, on using protein engineering to advance new treatments for cancer and autoimmune diseases. | |||
| Ep165: Zach Hornby on Tackling Cancer Drug Resistance | 26 sept. 2024 | 01:02:45 | |
Zach Hornby, CEO of San Diego-based Boundless Bio, on tackling cancer drug resistance. | |||
| Ep164: Ted Love and Alan Anderson on Raising the Bar for Sickle Cell Disease Patients | 05 sept. 2024 | 00:56:39 | |
Ted Love, chairman of BIO, and Dr. Alan Anderson, executive director of Sickle Forward, on how to improve quality of life for sickle cell disease patients around the world. | |||
| Ep163: Sarah Boyce on RNA Medicines for Muscle Diseases | 14 août 2024 | 01:08:19 | |
Sarah Boyce, CEO of San Diego-based Avidity Biosciences, on RNA medicines for rare muscle diseases. | |||
| Ep162: Sean McClain on AI for Biologic Drug Discovery | 16 juil. 2024 | 01:05:59 | |
Sean McClain, CEO of Absci, on using AI to speed up biologic drug discovery. | |||
| Ep161: Jeff Stein on a Long-Lasting Flu Drug | 01 juil. 2024 | 01:08:51 | |
Jeff Stein, CEO of San Diego-based Cidara Therapeutics, on a long-lasting drug against flu. | |||
| Ep160: Abe Ceesay on Precision Neuroscience | 17 juin 2024 | 01:08:48 | |
Abe Ceesay, CEO of Boston-based Rapport Therapeutics, on a precision medicine approach to neuroscience drug discovery. | |||
| Ep159: Jimi Olaghere on Being Functionally Cured of Sickle Cell Disease | 03 juin 2024 | 01:07:22 | |
Jimi Olaghere is one of the first patients to have been functionally cured of sickle cell disease with a CRISPR gene-edited cell therapy. | |||
| Ep158: David Younger and Randolph Lopez on SynBio & AI for Discovery | 20 mai 2024 | 01:00:44 | |
David Younger and Randolph Lopez, co-founders of A-Alpha Bio, on using synthetic biology and AI to discover new biologic drugs. | |||
| Ep157: Vineeta Agarwala of A16Z on Investing in AI for Drug Discovery | 01 mai 2024 | 00:56:33 | |
Vineeta Agarwala, general partner at A16Z's Bio & Health fund, on investing in AI for drug discovery. | |||
© My Podcast Data · Projet indépendant · Données issues d'Apple & Spotify